The DSIP 1987 sleep study did not establish a useful sleep benefit. Its most promising sleep-stage differences were already present before treatment. It also did not show more deep sleep. The researchers judged the improvement too small to matter much in treating insomnia, or persistent trouble sleeping.

That starting difference is the detail that changes how the study reads. More time in one sleep stage isn't convincing evidence that a medicine helped if the difference existed beforehand.

What did the DSIP 1987 sleep study ask?

J. M. Monti and colleagues asked whether DSIP—delta sleep-inducing peptide, a short chain of protein building blocks—could improve sleep over several nights.

Their 1987 paper in the International Journal of Clinical Pharmacology Research studied people with chronic insomnia. It used a double-blind crossover design: participants received both DSIP and placebo in separate periods. Placebo was the comparison treatment without DSIP. Double-blind means participants and the team assessing treatment didn't know which was being given.

Having each person try both treatments helps limit differences between people. It doesn't remove changes between nights or between study periods.

Who took part, and how did the nights work?

Six people took part, according to the Food and Drug Administration (FDA) presentation on July 24, 2026, slide 48. Its study summary describes four treatment nights per period and a four-day washout, a gap between periods intended to limit leftover effects.

The paper's abstract describes intravenous treatment, meaning it went into a vein. It reports a study dose of 25 nanomoles per kilogram, a measure based on body weight. That is a historical study detail, not a present-day prescription schedule.

The treatment-night pattern was:

Treatment night within each period What was being compared
Night 1 DSIP or placebo in that treatment period
Night 2 Another night under the same assigned treatment
Night 3 Another night under the same assigned treatment
Night 4 The last night of that treatment period

The crossover let the same people receive the other treatment in a separate period. The treatment-night numbers above don't label the entire laboratory stay. Baseline measurements—sleep recorded before treatment—provided another comparison.

Six people with persistent sleep problems are a narrow starting point. Their experience cannot establish how DSIP would affect people across different ages, illnesses or medication histories.

What did the sleep recordings measure?

The researchers used polysomnography, an overnight recording of brain waves and other body signals used to identify sleep and waking.

They tracked time asleep, time awake, awakenings and how long sleep took to begin. They also separated sleep into stages. This matters because an increase in one stage isn't an increase in every kind of sleep.

Stage 2 is a lighter phase of sleep. Slow-wave sleep is deep sleep, marked by slow brain waves. The older paper called its deep-sleep stages 3 and 4.

REM sleep is a different stage, marked by rapid eye movements and active brain waves. The study also considered sleep outside REM. These measurements describe the night's pattern; they don't, by themselves, tell whether someone feels better the next day.

Why the baseline sleep imbalance changes the result

The abstract reports more total sleep and more stage 2 sleep during DSIP treatment. Stage 1, deep sleep and REM sleep did not change.

The strongest-looking findings involved stage 2 and sleep outside REM. Those differences passed the study's statistical test, which asks how compatible a result is with chance. But the same differences were already present in the starting measurements.

That makes the treatment comparison hard to interpret. If sleep differed before DSIP was given, the later difference cannot simply be credited to DSIP. A crossover study still needs the starting measurements taken seriously.

Other measures moved in a favorable direction, including awakenings and time awake. They did not show a clear advantage over baseline or placebo in the authors' tests.

The authors' conclusion was restrained: the sleep improvement had little practical importance for treating patients. Calling this evidence that DSIP produces deeper sleep misses both the stage results and the baseline problem.

What can this study say about side effects?

It cannot establish dependable side-effect rates. A six-person, short-term experiment is too small to settle uncommon reactions or the effects of continued treatment.

The paper's abstract does not give a side-effect table. It therefore offers no reaction-by-reaction comparison that supports a percentage or a claim of zero adverse events, meaning unwanted medical problems during treatment.

Safety question What this evidence can support
How often did a particular reaction occur? The abstract provides no usable rate.
Does a brief study establish long-term safety? It cannot settle problems that develop with continued use.
Does intravenous study treatment establish safety for another preparation? A different preparation needs its own evidence.

A sleep finding and a safety finding answer different questions. Neither fills a gap in the other.

Did later research settle the question?

A 1992 trial by Bes and colleagues in Neuropsychobiology studied 16 people with chronic insomnia. Its abstract describes weak effects on recorded sleep and no improvement in participants' reported sleep quality.

That later experiment did not establish a major treatment benefit. The 1992 DSIP trial explainer covers its different design and results. The broader DSIP benefits review puts these small trials alongside the rest of the evidence.

Does the recent peptide policy change the evidence?

As of November 12, 2026, the day this article was written, an October 30 notice from HHS, the U.S. Department of Health and Human Services announces a nonbinding draft compounding policy. Compounding means preparing a medication for an individual patient's needs.

DSIP is absent from the policy's six-peptide Appendix A. The HHS peptide policy explainer covers its conditions. A policy about preparing medicines does not change what the 1987 sleep measurements showed.

What does this mean for a prescription today?

The old trial does not establish a current DSIP regimen or prove that a compounded version will have the same results. The DSIP dosing explainer discusses the limits of borrowing schedules from older studies.

DSIP prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. For an individual decision, the unresolved questions include meaningful sleep improvement, side effects and whether the proposed medication fits the person's medical history.